
Advicenne S.A (ALDVI) | Financial Analysis & Statements
Advicenne S.A. | Small-cap | Healthcare
Advicenne S.A. | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
9.5M
Total Liabilities
28.6M
Shareholders Equity
-19.1M
Cash Flow Metrics
Revenue & Profitability Trend
Advicenne S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 5.0M | 4.5M | 3.7M | 2.7M | 2.1M |
Cost of Goods Sold | 6.1M | 6.7M | 9.1M | 973.0K | 886.0K |
Gross Profit | -1.2M | -2.2M | -5.4M | 1.7M | 1.2M |
Gross Margin % | -23.6% | -49.8% | -144.9% | 63.8% | 58.5% |
Operating Expenses | |||||
Research & Development | - | 3.8M | 7.1M | 9.0M | 8.1M |
Selling, General & Administrative | - | 2.8M | 4.9M | 6.3M | 8.7M |
Other Operating Expenses | 3.2M | 1.9M | 1.8M | -1.1M | -1.4M |
Total Operating Expenses | 3.2M | 8.5M | 13.8M | 14.2M | 15.4M |
Operating Income | -9.1M | -6.5M | -10.3M | -12.4M | -14.1M |
Operating Margin % | -182.2% | -145.2% | -276.8% | -462.7% | -662.1% |
Non-Operating Items | |||||
Interest Income | 35.0K | 31.0K | 0 | 139.0K | 85.0K |
Interest Expense | 1.3M | 1.3M | 755.0K | 148.0K | 553.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -10.3M | -7.9M | -10.8M | -12.4M | -14.8M |
Income Tax | -372.0K | -324.0K | -602.0K | -11.0K | 29.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -6.5M | -7.5M | -10.3M | -12.4M | -14.8M |
Net Margin % | -129.9% | -168.8% | -276.4% | -462.1% | -695.4% |
Key Metrics | |||||
EBITDA | -6.3M | -6.2M | -9.7M | -12.0M | -14.0M |
EPS (Basic) | - | €-0.60 | €-1.05 | €-1.34 | €-1.73 |
EPS (Diluted) | - | €-0.60 | €-1.05 | €-1.34 | €-1.73 |
Basic Shares Outstanding | - | 12571136 | 9800028 | 9273881 | 8590835 |
Diluted Shares Outstanding | - | 12571136 | 9800028 | 9273881 | 8590835 |
Income Statement Trend
Advicenne S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 3.2M | 4.3M | 7.3M | 12.7M | 16.8M |
Short-term Investments | - | - | 2.0K | - | - |
Accounts Receivable | 3.2M | 1.6M | 1.1M | 802.0K | 818.0K |
Inventory | 1.7M | 1.7M | 982.0K | 717.0K | 735.0K |
Other Current Assets | - | 1.0M | 1.0M | 1.3M | 1.1M |
Total Current Assets | 8.8M | 9.3M | 11.8M | 16.6M | 20.8M |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.2M | 1.2M | 1.4M | 554.0K | 1.6M |
Goodwill | 302.0K | 275.0K | 135.0K | 167.0K | 38.0K |
Intangible Assets | 302.0K | 275.0K | 135.0K | 167.0K | 38.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | -1.0K | 1.0K | -1.0K | - | -1.0M |
Total Non-Current Assets | 701.0K | 3.1M | 2.0M | 2.3M | 3.2M |
Total Assets | 9.5M | 12.4M | 13.8M | 18.9M | 24.0M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 2.0M | 1.0M | 1.1M | 2.9M | 4.4M |
Short-term Debt | - | 1.5M | 1.5M | 165.0K | 4.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | -103.0K | 3.0M | 2.4M |
Total Current Liabilities | 8.7M | 5.0M | 4.0M | 6.1M | 11.4M |
Non-Current Liabilities | |||||
Long-term Debt | 18.2M | 18.3M | 18.5M | 12.1M | 9.2M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 10.0K | 10.0K | 6.0K | -2.0K | - |
Total Non-Current Liabilities | 19.9M | 20.0M | 20.3M | 12.5M | 9.4M |
Total Liabilities | 28.6M | 25.0M | 24.3M | 18.6M | 20.7M |
Equity | |||||
Common Stock | 2.5M | 2.5M | 2.0M | 2.0M | 1.7M |
Retained Earnings | -28.2M | -21.7M | -14.2M | -12.4M | -14.8M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -19.1M | -12.6M | -10.5M | 309.0K | 3.3M |
Key Metrics | |||||
Total Debt | 18.2M | 19.8M | 20.1M | 12.3M | 13.8M |
Working Capital | 141.0K | 4.3M | 7.8M | 10.5M | 9.4M |
Balance Sheet Composition
Advicenne S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -6.5M | -7.5M | -10.3M | -12.4M | -14.8M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | 304.0K | 480.0K | 347.0K | 605.0K |
Working Capital Changes | -1.5M | -495.0K | 4.1M | 314.0K | 796.0K |
Operating Cash Flow | -7.1M | -6.7M | -5.1M | -11.9M | -13.0M |
Investing Activities | |||||
Capital Expenditures | -91.0K | -1.2M | 81.0K | -297.0K | -575.0K |
Acquisitions | - | - | - | - | - |
Investment Purchases | -17.0K | 0 | 0 | -98.0K | -78.0K |
Investment Sales | - | 6.0K | 113.0K | - | - |
Investing Cash Flow | -108.0K | -1.3M | 194.0K | -451.0K | -694.0K |
Financing Activities | |||||
Share Repurchases | -17.0K | -26.0K | -17.0K | -56.0K | -41.0K |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 0 | 42.0K | 5.0M | 45.0K | 12.1M |
Debt Repayment | -1.1M | -1.2M | -222.0K | -225.0K | -254.0K |
Financing Cash Flow | -1.1M | 4.2M | 4.8M | 8.9M | 12.5M |
Free Cash Flow | -853.0K | -7.3M | -9.3M | -12.8M | -12.3M |
Net Change in Cash | -8.3M | -3.8M | -104.0K | -3.5M | -1.2M |
Cash Flow Trend
Advicenne S.A Key Financial Ratios
Valuation Ratios
Forward P/E
-30.12
Price to Sales
4.05
PEG Ratio
-30.12
Profitability Ratios
Profit Margin
-122.70%
Operating Margin
-121.78%
Return on Equity
33.89%
Return on Assets
-51.72%
Financial Health
Current Ratio
1.02
Debt to Equity
-0.95
Beta
1.26
Per Share Data
EPS (TTM)
€-0.81
Book Value per Share
€-1.55
Revenue per Share
€0.43
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
aldvi | 22.5M | - | - | 33.89% | -122.70% | -0.95 |
Abivax SA | 5.4B | -24.79 | -91.19 | -499.78% | 0.00% | -2.04 |
Medincell S.A | 656.2M | - | - | 112.65% | -66.50% | -4.11 |
Transgene S.A | 148.7M | - | 10.04 | -220.48% | 0.00% | 68.38 |
Adocia S.A | 153.1M | -8.38 | -38.22 | 301.75% | -76.88% | -3.83 |
Abionyx Pharma S.A | 135.3M | -30.41 | 17.51 | -56.76% | -96.27% | 36.69 |
Financial data is updated regularly. All figures are in the company's reporting currency.